Cargando…

Occurrence of Sézary syndrome following the initiation of anti-IL-5 treatment

Detalles Bibliográficos
Autores principales:	Barré, Mathilde, Amatore, Florent, Avenin, Morgan, Gorvel, Laurent, Olive, Daniel, Delaporte, Emmanuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Libbey Eurotext 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660101/ https://www.ncbi.nlm.nih.gov/pubmed/36065539 http://dx.doi.org/10.1684/ejd.2022.4268

Ejemplares similares

Incidence of mycosis fungoides and Sézary syndrome in the Netherlands between 2000 and 2020
por: Ottevanger, R., et al.
Publicado: (2021)

Large‐cell transformation is an independent poor prognostic factor in Sézary syndrome: analysis of 117 cases
por: Bontoux, Christophe, et al.
Publicado: (2022)

Imbalanced IL-1B and IL-18 Expression in Sézary Syndrome
por: Manfrere, Kelly Cristina Gomes, et al.
Publicado: (2023)

Microenvironment-dependent growth of Sezary cells in humanized IL-15 mice
por: Gao, Jie, et al.
Publicado: (2023)

Alemtuzumab as initial therapy for Sézary syndrome: A report of 2 cases
por: Brumfiel, Caitlin M., et al.
Publicado: (2020)

Alemtuzumab in refractory Sézary syndrome
por: Reifs, Carmen María Alcántara, et al.
Publicado: (2016)

Plantar keratoderma of Sézary syndrome
por: Fragkos, Konstantinos C.
Publicado: (2017)

Mycosis fungoides and Sézary syndrome
por: Jonak, Constanze, et al.
Publicado: (2021)

Mycosis fungoides and Sézary syndrome
por: Lee, Hyewon
Publicado: (2023)

Dupilumab-Associated Sezary Syndrome
por: Hamp, Austin, et al.
Publicado: (2023)

Clarification of Obeticholic Acid Dosing: Response to “Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation” by Quigley et al.
por: Feng, Cynthia
Publicado: (2018)

Integrated Genomic Analysis of Sézary Syndrome
por: Mao, Xin, et al.
Publicado: (2011)

A mouse model for the Sézary syndrome
por: Doebbeling, Udo
Publicado: (2010)

Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome
por: Moerman-Herzog, Andrea, et al.
Publicado: (2020)

Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
por: Gorvel, Laurent, et al.
Publicado: (2020)

Combining Biologics Targeting Eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in Allergic and Inflammatory Diseases
por: Pitlick, Mitchell M., et al.
Publicado: (2022)

The utility of bexarotene in mycosis fungoides and Sézary syndrome
por: Panchal, Manisha R, et al.
Publicado: (2015)

Sezary syndrome manifesting as posttransplant lymphoproliferative disorder
por: Afiat, Thanh-Phuong, et al.
Publicado: (2018)

The Role of Tumor Microenvironment in the Pathogenesis of Sézary Syndrome
por: Miyashiro, Denis, et al.
Publicado: (2022)

TOX Expression in Mycosis Fungoides and Sezary Syndrome
por: Pileri, Alessandro, et al.
Publicado: (2022)

Successful Treatment of Acrodermatitis Continua of Hallopeau with an Anti-IL-17A Agent
por: Inoue, Sae, et al.
Publicado: (2021)

BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer
por: Demerlé, Clemence, et al.
Publicado: (2021)

3D Tumor Models and Their Use for the Testing of Immunotherapies
por: Boucherit, Nicolas, et al.
Publicado: (2020)

EPHA4 is overexpressed but not functionally active in Sézary syndrome
por: Hameetman, Liesbeth, et al.
Publicado: (2015)

New Insights Into the Complex Mutational Landscape of Sézary Syndrome
por: Mirza, Abu-Sayeef, et al.
Publicado: (2020)

The Role of Tumor Microenvironment in Mycosis Fungoides and Sézary Syndrome
por: Liu, Zhaorui, et al.
Publicado: (2021)

Fatal Microangiopathic Hemolytic Anemia Due to Sézary Syndrome
por: Robertson, Jake C, et al.
Publicado: (2021)

Mycosis Fungoides and Sézary Syndrome: Microenvironment and Cancer Progression
por: Dobos, Gabor, et al.
Publicado: (2023)

Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland
por: Perez-Saez, Javier, et al.
Publicado: (2021)

The Occurrence of Naga Sore in Benares
por: Ghanekar, B. G.
Publicado: (1944)

GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT
por: Baron, Frédéric, et al.
Publicado: (2023)

Peripheral Neuropathy in Sézary Syndrome: Coincidence or a Part of the Syndrome?
por: Karadağ, Yeşim S., et al.
Publicado: (2013)

Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets
por: Saulite, Ieva, et al.
Publicado: (2016)

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME
por: Lechowicz, Mary Jo, et al.
Publicado: (2014)

Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis
por: Vural, Seçil, et al.
Publicado: (2018)

Double-positive CD4 and CD8 Sézary syndrome
por: Miyashiro, Denis, et al.
Publicado: (2017)

Pembrolizumab-associated tumor development in a patient with Sézary syndrome
por: Malachowski, Stephen J., et al.
Publicado: (2019)

Acute progression of the leukemic phase in mycosis fungoides and Sézary syndrome
por: Maredia, Hasina, et al.
Publicado: (2021)

Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario()()
por: Sanches, José Antonio, et al.
Publicado: (2021)

Images from the Haematologica Atlas of Hematologic Cytology: Sézary syndrome
por: Invernizzi, Rosangela
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_50nrua12lv26lveqbf75fefvnr